Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Stop being so negative.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by jopatcloon Oct 14, 2024 9:26am
35 Views
Post# 36265073

RE:RE:Stop being so negative.

RE:RE:Stop being so negative.
jopatclo wrote: The fud remenber 4.0 will be approved around the world.


Enough The fud remenber 4.0 will be approved around the world.and
 Overcoming Challenges in Echocardiography Interpretation with Next-Generation Solutions GEN3ECHO https://www.linkedin.com/pulse/overcoming-challenges-echocardiography-interpretation-hdcbf/?trackingId=W3drQD24aqdynyz1SVqxyA%3D%3D ASCEND’s Gen3Echo solution combines the latest in automated reporting workflow, AI-driven image review, advanced analytics, and seamless integration technologies to set a new standard for echocardiography that reduces diagnostic variability, improves workflow efficiency, and ultimately enhances patient outcomes. Remember Enougt the Fud marionnette a GranhamWalk avec 10 faux compte ici et sur ceo lol.(see The BEST automation and analysis on the PLANET GEN3EHO On website Ascend https://ascendcv.com/ Clic On integration see Ventripoint - The integration of Gen3Echo with Ventripoint’s innovative application of AI to echocardiography provides tremendous value to pediatric and adult echocardiographers in caring for their most complex patients.)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities